Fig. 5

Functional validation of NFκB and PI3K pathways: Real Time PCR-based validation of IGF2BP1 targets identified from the RIP-Seq data belonging to the A) NFκB and B) PI3K-Akt pathways in the Indian patient cohort (Total n = 111; E6R1+ n= 39, E6R1- (Other translocations) n= 26, No translocation n= 46) and MACS sorted CD19+ B-cell population as controls (n=5) (t test; p * <0.05, ** <0.01, *** <0.005, **** <0.0001) C) Schematic of the NFκB-luciferase reporter assay D) NFκB induction by TNFα (25ng/mL) determined by measuring luciferase activity after BTYNB mediated inhibition of IGF2BP1 in Reh-NFκB-Luc-dTomato cells